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Summary 
The ligand for CD40 has been recently identified as a 39-kd protein, gp39, expressed on the 
surface of activated CD4 + T helper cells (Th). In vitro, soluble CD40 and anti-gp39 have been 
shown to block the ability of Th to activate B cells, suggesting that gp39-CD40 interactions 
are important to T cell-dependent B cell activation. Here it is shown that in vivo administration 
of anti-gp39 dramatically reduced both primary and secondary humoral immune responses to 
erythrocytes and soluble protein antigens without altering responses to the T-independent type 
II antigen, trinitrophenyl-Ficoll.  Treatment of mice for 4 d with anti-gp39 inhibited the anti-sheep 
red blood cell (SRBC) response for at least 3 wk and inhibited the expression of all immunoglobulin 
isotypes in secondary responses to the protein antigen, keyhole limpet hemocyanin. To examine 
the direct effect of anti-gp39 on Th function, SRBC-immune Th cells from anti-gp39-treated 
mice were adoptively transferred and shown to be fully capable of providing help. These results 
suggest that anti-gp39 treatment does not cause Th deletion or anergy. Anti-gp39 may mediate 
its profound immunosuppressive effects on humoral immunity  by blocking gp39-CD40 interactions. 
Moreover, these studies establish gp39-CD40 as an important receptor-ligand pair for the targeting 
of therapeutic antibodies to control thymus-dependent humoral responses. 
T 
hymus-dependent (TD) 1 humoral immunity requires 
the participation of CD4 + Th, and constitutes an es- 
sential  arm of host immune defense to disease. Studies by 
Mitchison, Claman, Benacerraf, and Raft suggested that in- 
teractions between Th and B cells in vivo are essential in the 
development of humoral immunity. Moreover, in vitro studies 
have demonstrated that T cell-dependent antibody responses 
require activation of T  cells by dendritic cells followed by 
an interaction between activated Th cells and B cells (1, 2). 
The requirement for physical contact between Th and B cells 
in the humoral immune response cannot be replaced by lym- 
phokines, as all combinations of lymphokines have proven 
ineffective at inducing resting B cell growth and differentia- 
tion. Therefore, a unique cell contact-dependent signal tran- 
spires as a consequence of the physical interactions between 
Th and B cells which induces B cell activation. This contact- 
1 Abbreviations used in this paper: Chi-L6, chimeric L6; HIg, hamster Ig; 
HIM,  hyper IgM  syndrome; TD,  thymus  dependent;  TI,  thymus 
independent. 
dependent signal is believed to be transduced as a result of 
the binding of gp39 on activated Th to its receptor,  CD40, 
on B cells (3). 
CD40, a mitogenic receptor expressed on all mature B lyrn- 
phocytes (4, 5), is a member of the nerve growth factor receptor 
(NGFR) family of receptors (6). The ligand for CD40, gp39, 
is a type II membrane protein that is homologous to TNF-ot 
and -/3 (7,  8), other NGFR family ligands.  Evidence that 
CD40 is an important mitogenic receptor on B cells is de- 
rived from studies that show highly ef~cient triggering of 
human B cells by anti-CD40 and cofactors such as anti-CD20, 
anti-Ig, and lymphokines (7-12).  In the presence of these 
cofactors, anti-CD40 has been shown to initiate both B cell 
growth and differentiation. Similar to anti-CD40, gp39, ex- 
pressed as a recombinant membrane or soluble protein, also 
activates B cells in the presence  of costimulators (7,  13). 
gp39 is transiently expressed on activated  CD4 + Th in 
vitro (14) and is induced in vivo on CD4 + T cells as a re- 
sult of antigen administration (15). The CD4 + T cell popu- 
lation expressing gp39 in vivo has been localized in situjux- 
taposed to B cells producing antibodies to the immunizing 
antigen (15). In vitro and in vivo data suggest that during 
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of gp39 by CD4 + T  cells is the result of antigen presenta- 
tion (16). Once expressed, gp39 binds to CD40 and recipro- 
cally triggers B cell activation. The ability of a mAb specific 
for gp39, MR1, to block the capacity of gp39-bearing Th 
to activate B cells in vitro has implicated gp39 as an impor- 
tant molecule in T  cell-dependent B cell activation (17). 
Further evidence implicating gp39-CD40 involvement in 
humoral immune responses  has recently been provided by 
several groups demonstrating that mutations in the gene en- 
coding gp39 result in the inability of humans to respond to 
TD antigens (18-21). An immunodeficiency  characterized by 
failure to mount TD humoral immune responses, hyper-IgM 
syndrome (HIM), results in the expression of a defective gp39 
molecule that lacks CD40 binding capacity.  Although the 
B lymphocytes from these patients are reported to be normal 
(18, 19, 21), mutations in the gp39 molecule interrupt B cell 
triggering through CD40 and subsequent B cell activation 
and Ig production. 
The present study examines the ability of a mAb specific 
for gp39 to neutralize the function of gp39 in vivo. In vivo 
administration of anti-gp39 reduced primary as well as sec- 
ondary antibody responses  to exogenous TD antigens, but 
not the T-independent (TI)-type II antigen, TNP-Ficoll. Fur- 
thermore,  short-term  treatment with anti-gp39 produced 
prolonged suppression of humoral immune responses. Th cells 
from anti-gp39-treated mice were capable of providing help 
upon adoptive transfer, suggesting that anti-gp39 treatment 
did not result in deletion or anergy of responding Th in vivo. 
Evidence is presented supporting the hypothesis that anti- 
gp39 exerts its profound immunosuppressive effects by directly 
blocking gp39-CD40  interactions in vivo. 
Materials  and Methods 
Animals 
Female, 6-8-wk-old BALB/c  mice (The Jackson Laboratory,  Bar 
Harbor, ME) were used for the in vivo experiments presented in 
this study. Animals were maintained in the specific pathogen-free 
animal facility at Dartmouth Medical School. 
T Helper Cell Clones (Thl) 
D1.6, an I-Ad-restricted, rabbit Ig-specific  Thl clone (22) was 
obtained from Dr.  David Parker (University of Massachusetts, 
Worcester, MA). In this paper, D1.6 will be referred to as Thl. 
Reagents and Antibodies 
MILl, hamster anti-murine gp39 mAb  (17), was purified by 
DEAE HPLC from ascites fluid. Hamster Ig (HIg), used as a con- 
trol antibody, was purified similarly  from hamster serum (Accurate 
Chemical and Scientific Corp., Westbury, NY). RG7/7.6.HL, a 
mouse anti-rat K  chain (strongly  cross-reactive  with hamster K  chain) 
antibody, (RG7), (23) was conjugated with horseradish  peroxidase 
or FITC and used as a secondary reagent to detect MR1 and HIg. 
Affinity-purified  goat anti-mouse IgM, IgG1, IgG2a, IgG2b and 
IgG3 (Southern Biotechnology Associates, Birmingham, AL) were 
used as detection antibodies in the antigen-specific  ELISAs,  as well 
as in the total IgM and IgG1 ELISAs. EM95 (kindly provided by 
Dr. T. Waldschmidt, University of Iowa, Iowa City, IA) a mono- 
clonal anti-murine IgE, was used as the detection antibody for the 
IgE anti-KLH ELISA. Chimeric L6 (Chi-L6), a humanized IgG1 
specific for the tumor antigen L6 (24), was kindly provided by 
Bristol-Myers Squibb Pharmaceutical  Research Institute. Anti-CD4, 
GK 1.5 (25) was prepared by HPLC purification of ascites fluid. 
SRBC were purchased from Colorado Serum Co. (Denver, CO). 
Sea plaque agarose for use in anti-SRBC plaque assay  was obtained 
from FMC Corp. BioProducts (Rockland, MA). Baby  rabbit com- 
plement was purchased from Cedarlane  Laboratories  Ltd. (Hornby, 
ON, Canada). KLH (from Megathura crenulata)  was purchased from 
Calbiochem-Novabiochem  (La  Jolla, CA). CFA for immunizations 
was obtained from Sigma Chemical Co. (St. Louis, MO). TNP- 
SRBC, TNP-KLH, and TNP-BSA were prepared as previously  de- 
scribed (26). 
Immunizations for Generation of In  Vivo Primary and 
Secondary Antibody Responses 
Primary Immune Responses.  For eliciting primary antibody re- 
sponses to SRBC or TNP-SRBC, mice were immunized with 200 
/~1 of 1% SRBC or TNP-SRBC suspension (i.v.). The IgM, anti- 
SRBC response was assayed  5 d after administration  of antigen using 
a modification of the Jerne plaque assay (27). IgM anti-TNP re- 
sponses were measured by ELISA on day 6. Primary responses to 
the heterologous Ig Chi-L6 were generated by intraperitoneal im- 
munization of 100/~g Chi-L6 on alum per mouse. The serum IgM 
anti-Chi-L6 antibody response was measured after 7 d. Primary 
responses to TNP-Ficoll were generated by immunization with 25 
#g of TNP-Ficoll, i.p. The IgM anti-TNP response was measured 
on day 6 by ELISA. 
Secondary Immune Responses.  For generation of secondary hu- 
moral responses to KLH, animals were immunized with KLH in 
CFA (50/~g, i.p.). Mice were subsequently challenged with 10 t~g 
of soluble KLH (i.p.) 3 mo later. The anti-KLH antibody response 
was measured on day 7 from the serum of immune mice utilizing 
isotype-specific  ELISAs. Secondary antibody responses to Chi-L6 
were generated by challenging Chi-L6 immune mice with 10/xg 
soluble Chi-L6, i.p. The serum IgG1 anti-Chi-L6 antibody response 
was measured after 7 d. 
Anti-gp39  Treatment 
Sterile, HPLC-purified anti-gp39 (MR1) or HIg (as an antibody 
control) was administered  intraperitoneally  on days  0, 2, and 4 after 
immunization or challenge as indicated for each experiment. 
Antigen-specific ELISAs 
The antigen-specific  IgM, IgG1, IgG2a, IgG2b, IgG3, and IgE 
antibody titers were determined using isotype-specific ELISAs. 
Briefly, antigen,  (1  mg/ml of KLH, Chi-L6,  TNP16-BSA, or 
TNP2-BSA in PBS) was absorbed onto flexible polyvinyl micro- 
titer dishes, overnight at 4~  Plates were washed  and blocked  with 
PBS-1% FCS-sodium-azide.  Diluted serum samples were incubated 
for 2 h at 37~  Samples were washed and the antigen-specific  an- 
tibody  titers  determined  with  one  of the  following  alkaline- 
phosphatase-conjugated  detection antibodies: goat anti-mouse IgM, 
IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotechnology  Associates). 
The IgE-specific  ELISA  was detected  using biotin-conjugated  EM95 
followed by alkaline-phosphatase  avidin (Zymed, South San Fran- 
cisco, CA). All ELISAs were developed by reaction of alkaline- 
phosphatase with phosphatase substrate (Sigma Chemical Co.). 
Plates were analyzed  on an ELISA  reader (model MtL700; Dynatech 
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bitrary values based on the titration curve of a standard immune 
serum. All experimental groups were titered from 1:100 to 1:100,000, 
and the titer ascertained based on multiple point analysis. The levels 
of anti-KLH, anti-Chi-L6, and anti-TNP antibodies in unchallenged 
controls were below detection. 
IgM anti-SRBC phque-forming cell (PFC) response  of mice 
that received a total of 1.5 mg of anti-gp39  (500 #g/mouse 
on days 0,  2,  and 4) was reduced  99%  when  compared to 
the anti-SRBC  PFC response from control or HIg-treated 
mice (Fig.  1 A).  In addition,  administration  of as little as 
Detection of Serum Anti-gp39 
Quantitation of Intact Anti-gp39 in the Serum of Anti-gp39-treated 
Mice.  Serum from mice receiving 750/~g anti-gp39 (250 #g on 
days 0, 2, and 4) was obtained on days 7, 14, and 21 after initiation 
of anti-gp39 treatment.  The serum was run on a 7.5%  SDS gel 
under nonreducing conditions,  transferred to nitrocellulose, and 
blotted with HRPO-conjugated RG7. After chemiluminescent de- 
tection, areas of the blot corresponding to 150-165 kD were scanned 
and digitized using an Apple Scanner and the Image 4.1 software 
program (Apple Computer,  Inc., Cupertino,  CA). 
Analysis fir Biologically Active Anti-gp39 in the Serum of Treated 
Mice.  Anti-CD3-activated Thl, which express gp39, were stained 
with dilutions of serum from mice receiving 750/~g anti-gp39 (250 
/~g on days 0, 2, and 4) to determine the amount of biologically 
active gp39 remaining in the serum. Titrations of serum containing 
anti-gp39 were incubated with activated Thl cell clones for 30 min 
at 4~  followed by washing and subsequent  incubation with FITC- 
RG7 for 30 min at 4~  A  standard curve of mean fluorescence 
intensity vs anti-gp39 concentration was generated using purified 
anti-gp39. Samples were analyzed on a FACScan |  (Becton Dick- 
inson & Co., Mountain View, CA) and the percent anti-gp39 re- 
maining in the serum was deduced based on the anti-gp39 stan- 
dard curve. The level of anti-gp39 present in the serum at d7 was 
set at  100%. 
Adoptive  Transfer of Th  Cells 
Mice were immunized intravenously with 200/~1 of 1% SR.BC, 
and administered anti-gp39 or HIg (250/~g on days 0, 2, and 4). 
On day 7 the splenocytes from nonimmune or SR.BC-immune mice 
were removed, erythrocyte depleted, washed, and transferred in- 
travenously (50  ￿  106/mouse)  into irradiated recipients (600 rad) 
with or without  50  ￿  106 spleen cells from TNP-KLH primed 
(TNP-KLH-CFA, 50 #g, i.p.) mice as a source of immune B cells. 
At the time of transfer, mice were immunized intravenously with 
200 #1 of 1% TNP-SRBC. Serum IgG1 anti-TNP titers were ascer- 
tained on day 6 after transfer. 
Results 
Anti-gp39 Inhibits  the Generation of Primary Antibody Re- 
sponses to Erythrocyte Antigens.  The impaired TD immunity 
observed in patients with HIM, as well as the potent inhibi- 
tory effects of anti-gp39  and CD40-Ig on Th-dependent  B 
cell activation in vitro,  provided the basis for the  study of 
the  potential  immunosuppressive  effects  of anti-gp39  on 
humoral-mediated immunity in vivo. To investigate the role 
of gp39-CD40 interactions in primary TD humoral immune 
responses,  the effect of in vivo administration  of anti-gp39 
on the primary antibody response to SRBC was determined. 
Animals were immunized with SRBC and administered anti- 
gp39 mAb (or control HIg) over the course of 4 d. On day 
5, the primary anti-SRBC  antibody response of anti-gp39- 
treated, HIg-treated, and control mice was ascertained. The 
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Figure  1.  (.4)  Anti-gp39 inhibits the generation of primary anti-SRBC 
PFC. Mice (three per group) were administered 200/~1 of 1.0% SRBC, 
i.v., on day 0. On days 0, 2, and 4 mice were given either  100 or 500 
/lg of purified MR.1 (hamster anti-marine gp39, purified from ascites by 
DEAE HPI.C) or 500 #g of purified hamster Ig, i.p. The control group 
consists of mice receiving the immunization, but no antibody treatment. 
Spleens were removed from the mice on day 5 and the number of direct 
(IgM) anti-SRBC PFC was determined  by a modification  of the Jerne plaque 
assay. The data is representative of three such experiments. (/3) Prolonged 
immune suppression of primary anti-SRBC responses is induced by the 
administration of anti-gp39. Mice (three per group) were immunized with 
SRBC (200/11 of 1.0% SRBC, i.v.) and on day 0, 2, and 4, received 250 
/~g of anti-gp39 (O) or 250/ig hamster Ig (U), i.p. (Black  bar) The time 
of antibody administration. The anti-SRBC PFC response was determined 
on day 5 after immunization. Additional mice were challenged with an- 
tigen (200/11 of 1.0% SRBC i.v.) 7 or 14 d after initial antigen immuniza- 
tion and anti-gp39 administration. The anti-SRBC PFC was then assayed 
5 d later. The results are representative of three similar experiments. 
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gp39, reduced the anti-SRBC primary immune response by 
66%. Results from these experiments demonstrate that anti- 
gp39 treatment ablates primary antibody responses in vivo. 
The duration of the immunosuppressive  effects of anti-gp39 
on the primary humoral immune response to SRBC was sub- 
sequently examined.  Mice  immunized with  SRBC  were 
treated with anti-gp39 for 4 d and assayed at various later 
time points for the capacity to mount a primary anti-SRBC 
response.  In this set of experiments, all animals were im- 
munized with SRBC on day 0 and administered anti-gp39 
or HIg on days 0, 2, and 4. The IgM anti-SRBC PFC re- 
sponse was measured for one group on day 5.  Additional 
SRBC-immune groups were challenged with SRBC on day 
7 or 14. 5 d after each antigenic challenge (days 12 and 19, 
respectively),  the IgM anti-SRBC PFC response was mea- 
sured. The results of one such experiment are depicted in 
Fig. 1 B. As in Fig. 1 A, the primary anti-SRBC responses 
were inhibited 80-90%  5 d after anti-gp39 administration 
was begun. In addition, the primary anti-SRBC responses 
12 and 19 d after  anti-gp39 treatment were also inhibited 
~90%. These results demonstrate that brief anti-gp39 treat- 
ment results in a prolonged inhibition of primary antibody 
responses. 
Anti-gp39 Inhibits the Generation of Secondary Anti-KLH An- 
tibody Responses.  Experiments examining primary antibody 
responses suggest that gp39-CD40 interactions play a crit- 
ical role in the initiation of primary humoral immunity. 
However,  these experiments do not address whether gp39- 
dependent CD40 signaling is required for the generation of 
secondary antibody responses. Therefore, the effects of anti- 
gp39 administration on the secondary immune response to 
soluble challenge with KLH was determined in KLH-immune 
mice. 
Using schedules of anti-gp39 administration that reduced 
the primary anti-SRBC PFC response, experiments were de- 
signed to evaluate the effects of anti-gp39 treatment on the 
secondary antibody responses. In these experiments, KLH- 
immune mice (immunized 3 mo before with CFA and KLH) 
were challenged with soluble KLH (10/zg/mouse/i.p.). On 
the day of antigen challenge (day 0), mice were also given 
250/~g of anti-gp39 or HIg, followed by anti-gp39 or HIg 
on days 2 and 4. At days 7 (Fig. 2 A) and 14 (Fig. 2 B) after 
challenge with KLH, the mice were bled and the titers of 
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Figure 2.  Anti-gp39 inhibits the generation of secondary 
anti-KLH antibody responses. Mice (three per group) were 
immunized with KLH in CFA (50/~g/mouse, i.p.).  3 mo 
after immunization, mice were given a soluble boost with 
10/~g of KLH (i.p.). On days 0, 2, and 4, immune mice re- 
ceived 250/~g of anti-gp39,  i.p. (open bars) or 250/~g HIg 
(hatched ban). Serum from individual mice was collected on 
day 7 (A) or 14 (/3) after antigenic challenge, pooled, and 
levels of anti-KLH antibodies were determined using isotype- 
specific ELISAs. Units represent arbitrary values based on the 
titration curve of a standard immune  serum. All experimental 
groups were titered from 1:100  to 1:100,000  and the titer ascer- 
tained based on multiple point analysis. The levels of anti- 
KLH antibodies in unchallenged controls were below detec- 
tion. The SE within each group were always <10%. These 
results are representative of three such experiments. 
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bodies were determined. The results demonstrate several 
points: (a) challenge with soluble KLH induced an enduring 
secondary immune response that persisted for up to 14 d; 
(b) the administration of anti-gp39 significantly reduced the 
secondary anti-KLH response of the isotypes measured when 
compared to the administration of equal quantities of HIg; 
and (c) the immunosuppressive  effects of anti-gp39 appeared 
to be sustained for at least  14 d after the initiation of anti- 
gp39 treatment. Taken together, results from these experi- 
ments demonstrate that similar to primary humoral immune 
responses, the generation of secondary humoral immune re- 
sponses were also blocked by anti-gp39. 
Anti-gp39  Inhibits the Generation of Antibody Responses to 
Heterologous Ig.  Experiments depicted in Fig. 1 demonstrate 
the immunosuppressive activity of anti-gp39 during a pri- 
mary response to a strongly immunogenic  particulate antigen, 
SRBC. The cellular nature of erythrocytes makes them unique 
in their capacity to elicit strong immune responses. Heterol- 
ogous Ig molecules share this characteristic  of being highly 
immunogenic, and therefore provide an additional model an- 
tigen system with which to examine the effects of anti-gp39 
treatment on the generation of primary and secondary anti- 
body responses. Animals were immunized with a heterolo- 
gous Ig molecule, Chi-L6, a humanized mouse antitumor 
cell mAb, and treated with anti-gp39 or control HIg. After 
7 d, sera was collected and assayed for the production of IgM 
anti-Chi-L6 antibodies. In addition, mice were challenged 
with Chi-L6 14 d after initial immunization and anti-gp39 
treatment, and assayed for IgG1 anti-Chi-L6 antibody produc- 
tion on day 21. Fig. 3 depicts the results of one such experi- 
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Figure 3.  Anti-gp39 inhibits the generation of primary and secondary 
antibody responses to heterologous Igs. Mice (three per group) were im- 
munized intraperitoneally  with 100/~g Chi-L6 absorbed on alum. On 
days 0, 2, and 4, immune mice received 250/~g of anti-gp39, i.p. (open 
Mrs) or 250 #g HIg (hatched  bars). Serum from individual mice was col- 
lected on day 7 after initial  immunization  (for IgM) or antigenic challenge 
(for lgG1). The levels of anti-Chi-L6 IgM and IgG1 antibodies were de- 
termined using antigen-specific ELISAs. Units represent arbitrary values 
based on the titration curve or a standard immune serum. All experimental 
groups were titered from 1:100 to 1:100,000  and the titer ascertained based 
on multiple point analysis. The levels of anti-Chi-L6 antibodies in un- 
challenged controls were below detection. The results are representative 
of two separate experiments. 
merit. The primary antibody response to Chi-L6 in mice 
treated with anti-gp39 is inhibited by >90% when compared 
to HIg-treated mice. Moreover, the secondary, IgG1 response 
to Chi-L6 is similarly inhibited. These results demonstrate 
that anti-gp39 treatment ablates primary and secondary an- 
tibody responses to a second type of TD antigen, heterolo- 
gous Ig, as effectively as it suppresses responses to erythro- 
cyte and soluble protein antigens. 
Anti-gp39 Does Not Inhibit the Generation of Primary Anti- 
body Responses to the TI-Type II Antigen,  TNP-FicolI.  Al- 
though the previous experiments demonstrate that anti-gp39 
effectively blocks the generation of primary and secondary 
antibody responses  to TD  antigens in vivo, it  is unclear 
whether gp39-CD40 interactions play a role in the initia- 
tion of humoral responses  to T1 antigens. Data presented 
in the accompanying  paper (15) demonstrate that immuniza- 
tion with the TI-type II antigen, TNP-Ficoll, results in gp39 
expr~sion by Th cells in vivo. To address whether gp39-CD40 
interactions are necessary for the generation of antibody re- 
sponses to this TI antigen, the affect of anti-gp39 treatment 
on mice immunized with TNP-Ficoll, was assessed. Mice 
immunized with TNP-Ficoll or TNP-SRBC were treated 
with anti-gp39 or HIg and the IgM anti-TNP antibody re- 
sponse determined after 6 d. Fig. 4 A demonstrates that animals 
immunized with the TD antigen TNP-SRBC didt significant 
anti-TNP serum antibody responses. As predicted from the 
previously described experiments, anti-gp39 treatment dra- 
matically inhibits the primary anti-TNP response generated 
in these mice. In contrast, mice immunized with TNP-Fico11 
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Figure 4.  Anti-gp39 administration  does not inhibit the generation of 
primary antibody responses to TNP-Ficull.  (A) Mice (three per group) 
were immunized with 200/,1 1% TNP-SRBC, i.v. On days 0,  2, and 
4 mice received 250/~g anti-gp39 or HIg. On day 6, mice were bled and 
the IgM anti-TNP antibody titers determined by TNP16-BSA ELISA. (B) 
Mice (three per group) were immunized  with 25/~g TNP-Ficoll, i.v. On 
days 0, 2, and 4 mice received 250/~g anti-gp39 or HIg. On day 6 mice 
were bled and the IgM anti-TNP antibody titers determined by TNP16- 
BSA ELISA. Units represent arbitrary values based on the titration curve 
or a standard immune serum. All experimental groups were titered from 
1:100 to 1:100,000 and the titer ascertained based on multiple point anal- 
ysis. The anti-TNP titer of nonimmune  mice was 390 U. The results are 
representative of two separate experiments. 
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B); however, treatment with anti-gp39 does not inhibit the 
antibody response to TNP-Ficoll. Results from these experi- 
ments demonstrate that, unlike responses to TD antigens, 
anti-gp39 does not block the generation of humoral responses 
to TNP-FicoI1, suggesting that responses to TI antigens may 
be gp39 independent. 
Anti-gp39 Administration Does Not Functionally Delete SRBC- 
specific Th.  From the previous experiments, it is known that 
anti-gp39 interferes with the development of TD humoral 
immunity. However, the mechanism by which anti-gp39 treat- 
ment suppresses humoral responses is not dear. Immune sup- 
pression by anti-gp39 could be mediated by: (a) the negative 
signaling of gp39-bearing T cells causing Th anergy; (b) mAb- 
mediated cytotoxic deletion of anti-gp39 bearing CD4 + T 
cells; and/or (c) the blocking of gp39 binding to CD40. A 
series of experiments were performed to gain insight into 
which of these mechanisms may be operative in the protracted 
immune suppression observed with anti-gp39 therapy. To ex- 
plore the possibility that antigen-specific Th were deleted or 
anergized by anti-gp39 therapy, antigen-specific Th function 
from gp39-treated mice was measured by adoptive transfer. 
Briefly, mice were immunized with SRBC (to prime SRBC- 
specific  Th) and administered anti-gp39 or HIg (250/xg/mouse 
on days 0, 2, and 4). After 7 d, spleen cells from unimmunized 
mice or  SRBC-immune spleen  cells  from HIg-  or  anti- 
gp39-treated mice were adoptively transferred into recipient 
mice with TNP-immune spleen cells as a source of TNP- 
primed B cells. Mice were simultaneously challenged with 
TNP-SRBC, and the IgG1 anti-TNP titer ascertained on day 
5. SRBC-primed Th cells are required to elicit a secondary 
anti-TNP response in the recipient mice as demonstrated by 
the fact that recipients that received spleen cells from nonim- 
mune donors produced substantially lower IgG1 anti-TNP 
compared to those mice that received spleen cells from SRBC- 
primed animals (Fig. 5). More importantly, results of these 
experiments revealed that the SRBC helper activity from HIg- 
and anti-gp39-treated mice was similar, indicating that anti- 
gp39 treatment did not alter Th function or block the priming 
of Th. Moreover, antigen-responsive Th were not deleted or 
anergized as a result of anti-gp39 treatment, as they provided 
helper-effector  function upon transfer. 
In Vivo Clearance of Hamster Anti-gp39.  Previous studies 
have established  that anti-gp39 (MR1) blocks the binding 
of gp39 to CD40 (16) and thus support the hypothesis that 
the in vivo immunosuppressive effects of anti-gp39 are due 
to the blocking of gp39-CD40 interactions. If one assumes 
this hypothesis to be correct, the long-term immune sup- 
pression observed with anti-gp39 administration requires the 
persistence  of anti-gp39 in the host. To determine if anti- 
gp39 could be detected for the period of time that immune 
suppression was evident, the in vivo clearance rate of anti- 
gp39 from serum was determined. Mice were given a regime 
of antibody (3 x  250/xg anti-gp39) over the course of 4 d 
and assayed for the levels of serum anti-gp39 at 7,  14, and 
21 d after the initiation of antibody administration. Western 
blot analysis for nonreduced MR1 (160 kD) indicated that 
TSRBC  BTNP 
Hamster Ig  4" 
anti-gp39  4" 
Hamster Ig 
none 
nonimmune 
none 
I 
lOO 
I  I  I 
200  300  400 
IgG1 anti-TNP units 
Figure 5.  Anti-gp39 administration does not functionally delete SRBC- 
specific Th. Mice (three per group)  were immunized with SRBC (200 
/~1 of 1.0% SRBC, i.v.) and administered anti-gp39 or HIg (on days 0, 
2, and 4; 250/~g/d).  On day 7, the spleens from nonimmune  or SILBC- 
immune mice were removed and transferred (i.v., 50  x  106/mouse) into 
irradiated recipients (600 rad) with/without 50  x  106 spleen cells from 
TNP-KLH primed (KLH/CFA 50 #g, i.v.) mice as a source of immune 
B ceils. At the time of transfer, mice were also immunized with TNP- 
SRBC (200 ~tl of 1.0% TNP/SRBC). Serum IgG1 anti-TNP titers were 
ascertained on day 6 after transfer using a TNP2-BSA ELISA. Units rep- 
resent arbitrary values based on the titration curve of a standard immune 
serum. All experimental groups were titered from 1:100 to 1:100,000 and 
the titer ascertained based on multiple point analysis. The data are repre- 
sentative of two such experiments. 
intact, serum anti-gp39 could be detected for at least 21 d 
after the initiation of antibody treatment (Fig.  6 A).  The 
serum concentration of anti-gp39 in animals at 21 d was '~5% 
(based on scanning densitometry), when compared to the 
signals derived from serum of animals analyzed 7 d after ini- 
tiation of antibody therapy. 
Although it was  determined that intact  anti-gp39 was 
present in serum, it was also important to ascertain that the 
anti-gp39 was biologically active. Therefore, sera from mice 
that received 3 x  250/zg of anti-gp39 over the course of 
4 d were used to stain gp39-bearing Th (Fig. 6 B). The level 
of serum anti-gp39 3 d after the last injection (7 d after initi- 
ation of antibody treatment) was set at 100%.  14 d after the 
initiation of antibody therapy, '~10-15% of the biologically 
active anti-gp39 mAb was detected in the serum. 21 d after 
initiation of therapy,  2-3%  of anti-gp39 remained in the 
serum. Therefore, both the determination of intact gp39 by 
Western blotting and of biologically active anti-gp39 revealed 
that ,v5% of the anti-gp39 was present 21 d after beginning 
anti-gp39 therapy. These results demonstrate the half-life of 
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Figure  6.  Invivoclearanceofhamsteranti-gp39. Mice were administered 
3 ￿  250 #g of anti-gp39  on days 0, 2, and 4. On days 7, 14, and 21, the 
amount of remaining anti-gp39 was determined as follows: (A) serum (1.5 
/~l) was  electrophoresed  under  nonreducing conditions,  transferred  to 
nitrocellulose,  and blotted with HRPO-conjugated R.G7 (mouse anti-rat 
chain),  followed by chemiluminescent  detection.  Areas of blot corre- 
sponding to 150-165 kD were scanned and digitized. (B) Titrations of 
serum were used to stain activated Thl to determine the amount of bio- 
logically active anti-gp39 present in the serum. Activated Thl were stained 
with titrations of serum followed by FITC-anti-rat K chain (RG7).  The 
percent  anti-gp39  remaining in serum was deduced based on a standard 
curve of mean fluorescence intensity vs serum  concentration,  using day 
7 as 100%. (Black bar) The time of antibody administration.  The results 
are representative  of two such experiments. 
anti-gp39 to be approximately 12 d and offer evidence con- 
sistent with the hypothesis that prolonged suppression ofhu- 
moral immune responses by anti-gp39 is due to persistent 
blocking of Th function. 
Discussion 
The present study demonstrates that in vivo administra- 
tion of an anti-gp39 antibody which blocks gp39-CD40 in- 
teractions in vitro, results in profound inhibition of both pri- 
mary  and  secondary humoral immune responses  to  TD 
antigens, but not TI-type II antigens. In addition, this study 
demonstrates that anti-gp39 treatment does not block the 
priming of antigen-primed Th cells. Therefore, the gp39- 
CD40 ligand-receptor pair can be used as a target for the 
therapeutic manipulation of the humoral immune response. 
To gain insight into how anti-gp39 was exerting its im- 
munosuppressive effect on humoral immunity, the direct effects 
of anti-gp39 on Th function were addressed. The data indi- 
cate that SRBC-immune Th from anti-gp39-treated mice were 
fully capable of providing help upon adoptive transfer,  sug- 
gesting that anti-gp39 treatment did not cause Th deletion 
or anergy in vivo. These results led to the speculation that 
anti-gp39 mediates its immunosuppressive  effects by blocking 
gp39 binding to CD40 and not by the inactivation of gp39- 
bearing Th. In support of this hypothesis, in vitro studies 
have established that anti-gp39 blocks the binding of CD40 
to gp39 (17). Furthermore, biologically active anti-gp39 could 
be detected in serum for the period of time that immune sup- 
pression was apparent. Although only 5% of anti-gp39 was 
present in serum at a time when immune suppression was 
evident, it is possible that the local tissue concentrations of 
anti-gp39 in specific sites of secondary lymphoid organs is 
higher and clearance rates are slower than that of serum anti- 
gp39. Further insights are dearly needed to conclusively ad- 
dress the mechanism(s) of action of anti-gp39. Currently, 
studies are underway examining the effect of Fab and F(ab')2 
anti-gp39 on humoral immune responses so as to allow us 
to verify that anti-gp39-mediated inhibition is the result of 
gp39 blockade. 
Treatment of mice with anti-gp39 inhibited the primary 
immune response to SRBC and heterologous Ig >90% for 
prolonged periods of time. Assuming that anti-gp39 is medi- 
ating the inhibition by blocking gp39 function, these data 
implicate gp39-CD40 interactions as essential in the devel- 
opment of primary immune responses to TD antigens. Im- 
munohistochemical analysis establish  that gp39 is induced 
as a consequence of immunization with TD antigens and 
may be of functional significance. The in situ studies of gp39 
expression illustrate that the initial site of gp39-CD40 inter- 
actions during primary humoral immune responses is in the 
peripheral aspects of the periarteriolar lymphoid sheaths (PALS) 
and around the terminal arterioles  (TA) of the spleen (15). 
It is at these sites that conjugates between gp39-expressing 
Th and antigen-specific B cells were found juxtaposed, sug- 
gesting that the outer PALS is a major site of T-B cell inter- 
actions during primary humoral immune responses. There- 
fore, the PALS may be the site at which anti-gp39 interacts 
with gp39-expressing Th cells to ultimately inhibit T-B in- 
teraction and subsequent Ig production. Immunohistochemical 
analysis of the distribution of anti-gp39 in anti-gp39-treated 
mice is underway to determine if this is the case. 
Similar to primary responses, the secondary humoral im- 
mune response of mice primed to KLH in CFA was also shown 
to be inhibited by the administration of anti-gp39. Consis- 
tent with the reduction of anti-SRBC PFC by anti-gp39, 
reductions in serum antibodies titers to antigenic challenge 
were also observed. The serum titers of all anti-KLH Ig iso- 
types measured (IgM, IgG1, IgG2a, IgG2b, IgG3, and IgE) 
were reduced by the treatment of mice with anti-gp39. The 
effect of anti-gp39 administration was apparent for at least 
14 d after secondary challenge with antigen, establishing a 
persistent immune suppression by anti-gp39. Anti-gp39-medi- 
ated immune suppression of secondary responses to KLH is 
not unique to KLH, since secondary immune responses to 
heterologous Ig  and  heterologous erythrocytes (data  not 
shown) were also inhibited by anti-gp39 therapy.  The ana- 
tomical distribution of gp39-expressing Th was identical to 
that observed upon primary immunization, however, the fre- 
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over that observed during primary immune responses. No 
gp39-expressing Th were found in the germinal centers or 
follicles of immune spleen (15). Thus, it appears that B cells 
are triggered to respond to activated Th cells in the PALS 
and TA of the spleen and later migrate to the follicles and 
germinal centers. 
Although the in vivo studies demonstrate that anti-gp39 
effectively  blocks the generation of responses to TD antigens, 
it appears that gp39-CD40 interactions play little if any role 
in the initiation of humoral responses to antigens that have 
classically been characterized  as T  cell independent.  Data 
presented in the accompanying paper demonstrate that gp39- 
expressing Th cells were found subsequent to immunization 
with both TD and one TI-type II antigen, TNP-FicoI1. How- 
ever, based on our supposition that anti-gp39 is working via 
the blockade of gp39 function, the inability of anti-gp39 treat- 
ment to inhibit primary responses to TNP-Ficoll suggests 
that gp39-CD40 interactions are not required for the gener- 
ation of humoral responses to TI-type II antigens. There are 
reports (15) that humoral immune responses to TNP-Ficoll 
are greatly augmented by Th. Therefore, it appears that the 
response to TNP-Ficoll requires Th but not gp39 function. 
A more comprehensive group of TI antigens are now under 
study to evaluate the gp39 dependence of these antigens for 
inducing humoral immune responses. Using anti-gp39, one 
should be able to refine the definition of TI and TD antigens 
as gp39 dependent or independent. 
Recent studies on patients with HIM have provided genetic 
proof that gp39 is an essential component in TD humoral 
immunity (18-21). Patients with HIM are characterized by 
increased susceptibility to bacterial infections, associated  with 
low levels of IgG, IgA, and IgE,  a severe reduction in fol- 
licles and a complete lack of germinal centers (28). However, 
normal or increased levels of isohaemagglutinin, antityphoid, 
and Forrsman antibodies are typically observed in HIM pa- 
tients. In these patients, vaccination often results in normal 
primary (IgM restricted)  antibody responses, yet boosting 
rarely results in specific  IgG responses (29). Given the results 
presented herein demonstrating that gp39 inactivation pro- 
hibits TD immune responses, the question emerges as to how 
patients with HIM, a genetic inactivation  of gp39,  mount 
primary IgM responses. First,  many of the IgM responses 
observed in HIM patients  may be due to TI type antigens 
eliciting  restricted  immunoglobulin isotype  profiles. Our 
studies with TI antigens in mice indicate that the IgM re- 
sponses to TI type II antigens are gp39 independent. Second, 
some antigens that we consider TD in the mouse, may act 
as TI antigens in humans. Third, it is not clear that all muta- 
tions in gp39 result in complete functional inactivation  of 
the molecule and therefore some HIM patients may express 
partially functional TD responses. Indeed, it has been reported 
that activated T cells from at least one HIM patient weakly 
bound a soluble, recombinant form of CD40 (18). This ob- 
servation supports  the idea that some gp39 mutations may 
allow for the production of incomplete TD responses. Alter- 
natively, one could suggest that gp39-CD40 interactions per 
se are not essential to the development of primary immune 
responses. Following this logic, one must then deduce that 
the immunosuppressive effects of anti-gp39  administration 
on the primary immune response are due to the deletion of 
activated, gp39-bearing Th. However, this is inconsistent with 
the data presented. 
The focus of the present  study was to demonstrate the 
potential use of anti-gp39 in the control of TD humoral im- 
munity. Brief  treatment regimes with the anti-gp39 resulted 
in prolonged suppression, an attractive attribute of this ther- 
apeutic antibody. Of special interest may be the capacity of 
anti-gp39 to prevent primary and secondary humoral responses 
to other heterologous,  therapeutic  antibodies  such as Chi- 
L6. This would permit the exposure of patients to repeated 
administrations  of heterologous  therapeutic antibodies.  In- 
hibitory effects on humoral immunity have been observed 
with other mAbs,  i.e., anti-CD4 (27,  28). Although it is 
unclear how anti-CD4 mediates immune suppression, exten- 
sive deletion of CD4 + T cells is correlated with suppressive 
efficacy (30),  a phenomenon not observed with anti-gp39 
therapy (data not shown).  In addition to anti-CD4, it has 
been shown that the interference by CTLA-4 of CD28 trig- 
gering, a costimulatory molecule on Th ceils, also suppresses 
TD antibody responses (31) and blocks xenogeneic graft re- 
jection (32). Similar to anti-gp39  administration,  CTLA-4 
induced a state of prolonged immune suppression. Because 
anti-gp39  and CTLA-4 mediate their immunosuppressive 
effects at distinct  stages of the humoral immune response, 
coadministration of these two immunosuppressive drugs may 
provide additive or synergistic immunosuppressive effects on 
immunity. 
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